Park Avenue Securities LLC boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,294 shares of the biopharmaceutical company’s stock after acquiring an additional 1,225 shares during the period. Park Avenue Securities LLC’s holdings in Halozyme Therapeutics were worth $337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also modified their holdings of the company. Rise Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 1st quarter worth approximately $25,000. Principal Securities Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $34,000. First Horizon Advisors Inc. boosted its stake in Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares in the last quarter. Parkside Financial Bank & Trust acquired a new position in Halozyme Therapeutics during the 4th quarter valued at approximately $64,000. Finally, Headlands Technologies LLC grew its holdings in shares of Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,613 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.
Insider Transactions at Halozyme Therapeutics
In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at $803,876.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 40,000 shares of company stock valued at $1,858,100 in the last ninety days. 2.40% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Get Our Latest Analysis on HALO
Halozyme Therapeutics Trading Up 1.4 %
Shares of Halozyme Therapeutics stock opened at $52.36 on Monday. The company has a fifty day simple moving average of $45.31 and a 200-day simple moving average of $40.45. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 0.53 and a beta of 1.28. Halozyme Therapeutics, Inc. has a 12-month low of $32.83 and a 12-month high of $53.00. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
- Five stocks we like better than Halozyme Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Stock Analyst Ratings and Canadian Analyst Ratings
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Stocks to Consider Buying in October
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.